With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy ...

The international biotechnology company BeiGene is moving its legal headquarters from the Cayman Islands to Basel. In ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Cell and gene therapy (C&GT) is set to revolutionise treatment of complex diseases, offering new possibilities for patients.

Steven H. Stein currently works at Repare Therapeutics, Inc., as Director from 2024, Incyte Corp., as Chief Medical Officer & Executive Vice President from 2016, the University of Pennsylvania, as ...

She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

It's the second deal involving FAP in the pace of 24 hours, after Lantheus Holdings acquired rights to NTI-1309, a PET oncology imaging agent that targets FAP, from Noria Therapeutics. Novartis ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Here are 10 new shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Editor’s note: The drugs listed are in ...